Host-mediated Leishmania donovani treatment using AR-12 encapsulated in acetalated dextran microparticles. - Wikidata - wikimedia - TriplyDB

Host-mediated Leishmania donovani treatment using AR-12 encapsulated in acetalated dextran microparticles.

Host-mediated Leishmania donovani treatment using AR-12 encapsulated in acetalated dextran microparticles.

http://www.wikidata.org/entity/Q34509079

about

Development and physicochemical characterization of acetalated dextran aerosol particle systems for deep lung delivery.Antifungal therapeutics for dimorphic fungal pathogens.The celecoxib derivatives AR-12 and AR-14 induce autophagy and clear prion-infected cells from prions.

P2860

Q38816102-D0AE0A2F-9484-4126-A687-F641F95E9358 Q38959083-0C902230-0C42-4209-868B-36184D5C4DB3 Q46240779-BD5DDAFD-00C8-48E4-9935-695343C3F2BA

P2860

Host-mediated Leishmania donovani treatment using AR-12 encapsulated in acetalated dextran microparticles.

http://www.wikidata.org/entity/Q34509079

description

2016 nî lūn-bûn

@nan

2016 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

Host-mediated Leishmania donov ...... alated dextran microparticles.

@ast

Host-mediated Leishmania donov ...... alated dextran microparticles.

@en

Host-mediated Leishmania donov ...... alated dextran microparticles.

@nl

type

label

Host-mediated Leishmania donov ...... alated dextran microparticles.

@ast

Host-mediated Leishmania donov ...... alated dextran microparticles.

@en

Host-mediated Leishmania donov ...... alated dextran microparticles.

@nl

prefLabel

Host-mediated Leishmania donov ...... alated dextran microparticles.

@ast

Host-mediated Leishmania donov ...... alated dextran microparticles.

@en

Host-mediated Leishmania donov ...... alated dextran microparticles.

@nl

P1433

Q34509079-14463E77-40AA-448C-8988-EA080EADE98D

P1476

Q34509079-7A7666DE-A195-419E-B31B-5324D7BEB648

P2093

Q34509079-2B7F9CEC-D057-4424-9484-4E8C3EB8CBD1

Q34509079-3F3F0622-FC66-4873-9A27-0A8E3192D2B1

Q34509079-698E9FBE-135A-4D29-88BC-9B887280A75E

Q34509079-757E8E8D-F730-4206-A02B-8CA7676D2588

Q34509079-98716D88-1152-40FB-88E6-13B0B0286895

Q34509079-9B7375C2-D4A3-4A2E-8C19-D11B24BD14EC

Q34509079-9F377BBA-B832-45D3-ACFB-7DFB3A6FF22D

Q34509079-CCF9FA1B-71E8-4122-BED3-87C0BFF3C1AA

Q34509079-F50AF83C-17D1-4C8A-9437-E14582014F60

P2860

Q34509079-072BA36F-DCB4-4D91-B2D3-B5CA73790FB5

Q34509079-0B28C748-245F-49D3-ABC2-435568429482

Q34509079-0E560E04-2AF4-4BA1-AD07-F5213339A44B

Q34509079-14D1A701-A936-477E-8181-8E825EA0DCCE

Q34509079-14D472D8-E6D0-402D-87D8-DD4050866825

Q34509079-177059BB-721A-4D25-B807-817CF87461FF

Q34509079-1790067D-F6CC-4557-8BFD-263817FFB072

Q34509079-1893D61E-AA5C-467C-B677-9B4074F45675

Q34509079-1A117D6F-4B61-425C-885B-03C65F6BEE20

Q34509079-20730167-D8DB-4945-B40E-FF40793C9E46

P304

Q34509079-79CC6F9C-C526-47A2-8A58-8E0CFC39EA33

P31

Q34509079-D97B472E-A64F-4EB8-BBEE-22A8D589DA5B

P356

Q34509079-1777081D-0BBB-49FC-B424-9EE5C939CEA3

P407

Q34509079-AA212C6A-259A-415D-8C32-B67FCE69D372

P433

Q34509079-1B0974EC-61EB-44DD-93B0-7F905F62B7EA

P478

Q34509079-FEE21535-9C87-4FD8-A758-1746BFBFA440

P50

Q34509079-F4B5280F-61DF-4F06-A9E2-7475D10AC758

P577

Q34509079-B43940E0-D239-424E-96DB-13A80BEB99CD

P5875

Q34509079-DE62B40E-E023-4E14-86F1-B81D706EFD18

P698

Q34509079-4382D681-EFD4-4558-9625-AD7DF06E472E

P921

Q34509079-EDE613ED-EFA1-4D40-9976-86466DD61315

P932

Q34509079-B3D4BC93-75D7-4FE7-970D-F505B9EF1DEC

P356

J.IJPHARM.2016.01.004

P1433

International Journal of Pharmaceutics

P1476

Host-mediated Leishmania donov ...... talated dextran microparticles

@en

P2093

A R Sataoskar

http://www.w3.org/2001/XMLSchema#string

E M Bachelder

http://www.w3.org/2001/XMLSchema#string

H Borteh

http://www.w3.org/2001/XMLSchema#string

K J Peine

http://www.w3.org/2001/XMLSchema#string

M A Collier

http://www.w3.org/2001/XMLSchema#string

S Gautam

http://www.w3.org/2001/XMLSchema#string

S Oghumu

http://www.w3.org/2001/XMLSchema#string

S Varikuti

http://www.w3.org/2001/XMLSchema#string

T L Papenfuss

http://www.w3.org/2001/XMLSchema#string

P2860

Delivery of host cell-directed therapeutics for intracellular pathogen clearance

Successful treatment of drug-resistant cutaneous leishmaniasis in humans by use of imiquimod, an immunomodulator

GRP78/BiP/HSPA5/Dna K is a universal therapeutic target for human disease

Mononuclear cell recruitment, granuloma assembly, and response to treatment in experimental visceral leishmaniasis: intracellular adhesion molecule 1-dependent and -independent regulation

Five-year field results and long-term effectiveness of 20 mg/kg liposomal amphotericin B (Ambisome) for visceral leishmaniasis in Bihar, India

Leishmaniasis: Middle East and North Africa research and development priorities

Sodium Stibogluconate (SSG) & Paromomycin Combination Compared to SSG for Visceral Leishmaniasis in East Africa: A Randomised Controlled Trial

Influence of clinical status and parasite load on erythropoiesis and leucopoiesis in dogs naturally infected with leishmania (Leishmania) chagasi

Pharmacological exploitation of an off-target antibacterial effect of the cyclooxygenase-2 inhibitor celecoxib against Francisella tularensis.

Toll-like receptor 3 agonist protection against experimental Francisella tularensis respiratory tract infection

P304

186-194

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.IJPHARM.2016.01.004

http://www.w3.org/2001/XMLSchema#string

P407

P433

1-2

http://www.w3.org/2001/XMLSchema#string

P478

499

http://www.w3.org/2001/XMLSchema#string

P50

Kristy M. Ainslie

P577

2016-01-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

289497088

http://www.w3.org/2001/XMLSchema#string

P698

26768723

http://www.w3.org/2001/XMLSchema#string

P921

P932

5730989

http://www.w3.org/2001/XMLSchema#string